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ABSTRACT:
Two alternatively spliced variants of an orphan
Caenorhabditis elegans G-protein-coupled receptors
(GPCRs; Y58G8A.4a and Y58G8A.4b) were cloned and
functionally expressed in Chinese hamster ovary (CHO)
cells. The Y58G8A.4a and Y58G8A.4b proteins (397 and
433 amino acid residues, respectively) differ both in
amino acid sequence and length of the C-terminal tail of
the receptor. A calcium mobilization assay was used as a
read-out for receptor function. Both receptors were
activated, with nanomolar potencies, by putative peptides
encoded by the ﬂp-18 precursor gene, leading to their
designation as FLP-18R1a (Y58G8A.4a) and FLP-18R1b
(Y58G8A.4b). Three Ascaris suum neuropeptides AF3,
AF4, and AF20 all sharing the same FLP-18 C-terminal
signature, -PGVLRF-NH2, were also potent agonists. In
contrast to other previously reported C. elegans GPCRs
expressed in mammalian cells, both FLP-18R1 variants
were fully functional at 378C. However, a 37 to 288C
temperature shift improved their activity, an effect that
was more pronounced for FLP-18R1a. Despite differences
in the C-terminus, the region implicated in distinct G-
protein recognition for many other GPCRs, the same
signaling pathways were observed for both Y58G8A.4
isoforms expressed in CHO cells. Gq protein coupling
seems to be the main but not the exclusive signaling
pathway, because pretreatment of cells with U-73122, a
phospholipase inhibitor, attenuated but did not
completely abolish the Ca2+ signal. A weak Gs-mediated
receptor activation was also detected as reﬂected in an
agonist-triggered concentration-dependent cAMP
increase. The matching of the FLP-18 peptides with their
receptor(s) allows for the evaluation of the pharmacology
of this system in the worm in vivo. # 2007 Wiley
Periodicals, Inc. Biopolymers (Pept Sci) 90: 339–348,
2008.
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INTRODUCTION
F
MRFamide-like peptides (FLPs also known as FaRPs)
are the largest and most diverse family of neuropeptides
known.1–3 Caenorhabditis elegans contains a very large
and diverse family of neuropeptide genes. From at least
109 genes encoding over 250 potential neuropeptides
identiﬁed in this nematode, more than 70 FLPs have been pre-
dicted and/or identiﬁed. Many have been found to play roles in
vital functions such as locomotion, reproduction, and social
behavior (for review see Ref. 3 and references within). Many of
the C. elegans peptides are identical or highly homologous to
those isolated or predicted in parasitic nematodes, including
Ascaris suum, Haemonchus contortus, Ancylostoma caninum,
Heterodera glycines, and Meloidogyne arenaria, suggesting that
the function of these peptides is similar across species.4,5
Neuropeptide–receptor matching is needed to gain a bet-
ter understanding of the biological function of these systems
in situ. If that function is found essential for the maintenance
of the parasite in the host, the receptor deﬁned high-
throughput screens could be established for ﬁnding nonpep-
tidic small molecules, either receptor agonists or antagonists,
as potential antiparasitic drug candidates.6–9
Despite intense efforts in many laboratories over the last
decade, most of the C. elegans neuropeptide G-protein-
coupled receptors (GPCRs) remain orphans, as only a few
have been matched with their native ligands.10–16 Functional
expression of C. elegans neuropeptide GPCRs in mammalian
expression systems has been challenging and problematic,
mainly due to the apparently poor compatibility of mamma-
lian G-proteins and other accessory proteins with heterelo-
gously expressed nematode receptors.
In this report, we describe functional annotation of two
spliced variants of the orphan C. elegans G-protein-coupled
receptor Y58G8A.4 as receptors for peptides predicted to be
encoded on the ﬂp-18 precursor gene, designated FLP-18R1a
(Y58G8A.4a) and FLP-18R1b (Y58G8A.4b).
EXPERIMENTAL
Materials
The synthetic peptides used in the study were purchased from Aus-
pep Pty. (Parkville, Australia). The mutant Chinese hamster ovary
cell line CHO-10001A (referred to hereafter as CHO cells), cell cul-
ture media, transfection, and various assay reagents were as previ-
ously described.11,12,17,18 U-73122 (phospholipase C inhibitor) and
its inactive analog U-73343 were obtained from the Upjohn/Phar-
macia/Pﬁzer compound collection.19
Cloning and Plasmid Preparation
Molecular biological techniques followed either manufacturer’s rec-
ommendations or general protocols.20 Initial attempts to clone the
cDNA corresponding to Y58G8a.a using RT-PCR and PCR primers
based on the predicted sequence (Wormpep release 23) were unsuc-
cessful (not shown). Further experimentation using various combi-
nations of the ﬂanking primers and sense/antisense internal primers
suggested that the 30 end of the open reading frame (ORF) was
incorrectly predicted. PCR ampliﬁcation using a C. elegans strain
N2 mixed stage cDNA library (Strategene, La Jolla, CA) along with
an internal sense primer in combination with a vector primer gave
two PCR products that corresponded to intact Y58G8a.a ORFs.
PCR primers were designed based on the new 30 ends and were used
to amplify the intact ORFs. PCR products were cloned into the eu-
karyotic expression vector pCR3.1 (Invitrogen, Carlsbad, CA), the
only modiﬁcation being the incorporation of a Kozak consensus
sequence (GCCGCC) before the initiator methionine (ATG) to opti-
mize translational initiation.21 The DNA sequence of the clones was
veriﬁed before transfection. The sequences are now correctly
described in GenBank entry AC006808, hypothetical proteins
Y58G8A.4a and Y58G8A.4b (referred to as FLP-18R1a and FLP-
18R1b, respectively, in this report). The ORF for each variant was
cloned directly into pCR3.1 to yield ﬂp-18-R1a/pCR3.1 and ﬂp-18-
R1b /pCR3.1 plasmids.
Phylogenetic Analysis
The amino acid sequences of the*60 predicted Family A (rhodopsin-
like) C. elegans peptidergic GPCRs were obtained through Wormpep.
For all of the sequences noted in the subgroup shown in Figure 1,
amino acid sequences deduced from cloned full-length cDNAs were
used in the alignment (unpublished observation). A group of *250
additional vertebrate and invertebrate GPCRs, chosen to cover the
spectrum of related peptidergic GPCRs, along with a smaller group
(*30) of representative aminergic GPCRs, were aligned using Clus-
talX,22 followed by manual editing. ClustalX was then used to generate
a neighbor-joining phylogenetic tree. The subgroup shown in Figure 2
is excerpted from that larger tree. For purposes of this publication,
only the C. elegans members of the subgroup are shown. The graphic
shown in Figure 2 was generated using Treeview.23
Cell Cultures, Transfection, Stable Cell Line
Generation and Membrane Preparation
CHO cells were cultured and transfected as described ear-
lier.11,12,17,18 The ﬂp-18R1a/pCR3.1 or ﬂp-18R1b /pCR3.1 plasmids
(5 lg DNA/10 cm plate) were used for transfections. The cells were
harvested 24 h after transfection and membranes were prepared as
described.11,12 In cases where a 37 to 288C shift was implemented,
media were supplemented with 0.1M HEPES pH 7.4 and the trans-
fected cells were ﬁrst incubated at 378C for 24 h posttransfection
and then moved to a humidiﬁed 288C/3% CO2 incubator for an
additional 16–24 h before harvesting for membrane preparation or
receptor signaling experiments.
To generate stable cell lines expressing Y58G8A.4a/FLP-18R1a or
Y58G8A.4b/FLP-18R1b, the transfected CHO cells were cultured in
complete DMEM media at 378C in a humidiﬁed atmosphere of 5%
CO2 in air for 24 h and then split 1:50, 1:100, and 1:200 into com-
plete DMEM media additionally supplemented with geneticin
(G418) initially at 1.0 mg/ml and then after 10 days at 0.5 mg/ml.
Individual colonies were selected, grown, and propagated in the
complete DMEM media supplemented with 0.5 mg/ml G418.
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Radioligand Preparation and Receptor Binding Via
Scintillation Proximity Assay
[125I-Y8]-DVPGVLRF-NH2 was prepared by radio-iodiation of
[Y8]-DVPGVLRF-NH2 using the chloramine T procedure. The
crude products were separated by RP-HPLC on a Vydac C18, 0.45
3 15 cm column using a 0.1M ammonium acetate pH 6.5/acetoni-
trile system. The radioactive fractions with retention time corre-
sponding to that of the cold [3-mono-iodoY8]-DVPGVLRF-NH2
standard were collected into vials containing capture buffer (0.1M
Na2HPO4, pH 8.0, with 0.5% BSA, 0.1% Triton 100X, and 0.05%
Tween-20). Transfected cell membranes (prepared from clonal cells
cultured with a 37 to 288C shift) were incubated for 30 min at room
temperature with occasional shaking with wheat germ agglutinin-
coated scintillation proximity assay (SPA) beads (Amersham Phar-
macia Biotech, Piscataway, NJ) in assay buffer (20 mM HEPES, 10
mM MgCl2, pH 7.4, 200 lg membrane protein/20 mg beads/ml).
After centrifugation at 1200g for 10 min the beads were resuspended
in the assay buffer. In saturation binding experiments, each well in
96-well SPA plates (Wallac, Turku, Finland) received: 60 ll assay
buffer, various concentrations of [125I-Y8]-DVPGVLRF-NH2 diluted
into assay buffer (20 ll) and 20 ll reconstituted membrane-coated
SPA beads suspension (1.5 lg membranes/150 mg beads) to result
in a total volume of 100 ll/well. Nonspeciﬁc binding (NSB) was
determined in the presence of 10 lM DVPGVLRF-NH2 at each ra-
dioligand concentration. Plates were counted on a Wallac 1450
Microbeta counter continuously and the 2 h counts, corrected for
NSB, were used for Kd and Bmax determinations. Competitive dis-
placement methods were similar to those used for determination of
the saturation curve except that a ﬁxed [125I-Y8]-DVPGVLRF-NH2
concentration was used added in 10 ll assay buffer (40 pM ﬁnal),
followed by the addition of increasing peptide concentrations, also
in 10 ll assay buffer. Each treatment was run in duplicate. Total
binding was determined in the absence of any peptides and *10%
of the label was added with 80% speciﬁc binding at the highest pep-
tide concentrations used (10 lM).
FIGURE 1 Alignment of amino acid sequences of the two isoforms of the Y58G8A.4 receptor,
Y58G8A.4a (FLP-18R1a) and Y58G8A.4b (FLP-18R1b). Predicted transmembrane domains are
boxed.
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cAMPAssay
Clonal cells were plated in 96-well plates (1.5 3 104 cells/well) and
incubated at 378C overnight. Before cAMP experiments, the media
were aspirated, replaced with plain DMEM (without serum), and
the cells were equilibrated for 1 h at 378C. The cells were then chal-
lenged with peptides, serially diluted in DMEM, for 20 min at 378C
followed by cell lysis and cAMP determination using a competitive
ELISA method according to the manufacturer’s protocol (Applied
Biosystems, Bedford, MA).24
Calcium Mobilization Assay
Assays were run using a 96-well ﬂuorescence imaging plate reader
(FLIPR) (Molecular Devices, Sunnyvale, CA) essentially as described
earlier12,18 either with clonal cell lines or cells transiently transfected
with the ﬂp-18R1a/pCR3.1 or ﬂp-18R1b/pCR3.1 plasmids and
plated at 2 3 104 cells/well 24 h after transfection. In experiments
incorporating a 37 to 288C temperature shift, cells plated in black-
walled 96-well plates were ﬁrst incubated at 378C for 24 h and then
at 288C for 16–24 h before testing in complete media supplemented
with 10 mM HEPES. Cell loading was with 4 lM FLUO3 (Molecular
Devices) in the presence of 2.5 mM probenecid.12,18 In experiments
with U-73122 (phospholipase C inhibitor), or its inactive analog U-
73343, these compounds were added 10 min before peptide chal-
lenge (at a ﬁnal concentration of 10 lM) in 10 mM HBSS/10 mM
HEPES/2.5 mM probenecid containing 0.1% DMSO. In yet another
experiment, plated cells were incubated with pertussis toxin (PTX,
100 ng/ml) overnight before peptide challenge.
Data Analysis
Data analysis was performed using GraphPad software (GraphPad,
San Diego, CA). Dose–response curves (Ca2+, cAMP, and binding
data) were analyzed using nonlinear regression analysis. In competi-
tion binding experiments, binding constants (Ki) were calculated
from the equation: Ki ¼ (IC50)/(1 + F/Kd) where F is the concentra-
tion of [125I] ligand and Kd is the dissociation constant of the
ligand. Each treatment was run in triplicate, unless otherwise indi-
cated, values were expressed as means6 SEM.
RESULTS
Cloning of Y58G8A.4a and Y58G8A.4b and
Phylogenetic Analysis
PCR ampliﬁcation using a C. elegans cDNA library as tem-
plate, using an internal sense primer in combination with a
vector primer, yielded two PCR products that corresponded
to intact Y58G8A.4 ORFs. PCR primers designed on the cor-
rect 30ends were then used to amplify the intact ORFs. The
deduced proteins encoded by the ORFs of splice variants
Y58G8A.4a and Y58G8A.4b are 397 and 433 amino acid
long, respectively (Figure 2). Both proteins are predicted to
have seven transmembrane domains, three extracellular and
three intracellular loops along with a C-terminal tail, a topol-
ogy consistent with the structure of G-protein-coupled
receptors. The ﬁrst 364 amino acids are identical for both
variants, while the Y58G8A.4b protein is 36 residues longer
and has some different amino acids in the C-terminal 365–
397 segment when compared with the shorter splice variant
Y58G8A.4a (Figure 1). The Y58G8A.4 receptors are most
closely related to three orphan C. elegans GPCRs ZC412.1,
C53C7.1, and C56G3.1 as well as to the previously matched
GPCRs C10C6.2 (a FLP-15 receptor12), C39E6.6 (also known
as NPR-113 or a FLP-21/AF9 receptor11), and C16D6.2, a
second FLP-18 receptor deorphanized by our group,10 which
will be described in a separate report.
Matching of Both Isoforms of Y58G8A.4 with FLP-18
Peptides and Other -VPGVLRF-NH2 Peptides
Receptor–ligand matching was detected by functionally
expressing both Y58G8A.4a and Y58G8A.4b in CHO
cells (transient transfections) using a 37–288C cooling step,
as described for two previously deorphanized C. elegans
GPCRs.11,12 A collection of over 150 synthetic peptides repre-
senting a variety of C. elegans and other invertebrate FMRFa-
mide-related peptides (based on both known and predicted
sequences) was used as a source of potential activating
ligands.11,12 A Ca2+ mobilization assay in an FLIPR format
was performed in a 96-well plates as a readout for receptor
activation in response to a challenge with individual pep-
FIGURE 2 Phylogenetic analysis of the C. elegans GPCRs. The
two isoforms of the FLP-18 receptor described in this report,
Y58G8A.4a and Y58G8A.4b are shown in bold. Other deorphanized
receptors for which ligands have been identiﬁed are underlined (see
text for more details).
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tides, tested at 5 lM. The strongest signal was detected for
peptides with a C-terminal -VPGVLRF-NH2 motif, which
included not only the C. elegans FLP-18 peptides but also
three A. suum FMRF-amides, GDVPGVLRF-NH2 (AF4),
AVPGVLRF-NH2 (AF3), and MPGVLRF-NH2 (AF20).
Hits from the initial 5 lM screen were later tested in a full-
concentration response format with clonal cell lines. Data
shown in Table I are EC50 values determined by FLIPR using
CHO cells stably expressing either Y58G8A.4a or Y58G8A.4b
and cultured at 378C, after it was found that both receptors
are fully functional at this temperature (see below). EC50 val-
ues for the C. elegans FLP-18 peptides and A. suum peptides
with the common FLP-18 C-terminal motif -VPGVLRF-NH2
were in the nanomolar range for activation of both receptor
isoforms. The A. suum AF3 peptide, AVPGVLRF-NH2, was
the most potent agonist for both receptor variants (EC50 7.6–
13.1 nM). The least potent peptide in the FLP-18 series was
DFDGAMPGVLRF-NH2 (EC50 117.2–124.0 nM), which has
the longest N-terminal extension (Table I). The cognate ligand
for the C. elegans NPR-1 receptor,11,13 GLGPRPLRF-NH2
(also known as AF9 or FLP-21 peptide), with a slightly differ-
ent C-terminal motif than the FLP-18 peptides also activated
both FLP-18R1a and FLP-18R1b, although with a consider-
ably lower potency (EC50 254–267 nM).
With regard to other C. elegans peptides, most of them
did not titrate down below 5 lM, except for one FLP-1 pep-
tide (SQPNFLRF-NH2, EC50 values 1.7–4.7 lM) and also
four FLP-3 peptides (Table I). The latter activated both re-
ceptor isoforms with the potency in the 0.9–2.9 lM range
(Table I). Based on these results, it is evident that the most
potent peptides by far are those encoded on ﬂp-18, and that
is why we believe that these peptides are the endogenous
ligands for the Y58G8A.4/FLP-18 receptor.
Temperature-Dependent Functional Expression of
Y58G8A.4a and Y58G8A.4b
Temperature-dependent functional activity of FLP-18R1a and
FLP-18R1b was tested by using a single FLP-18 peptide,
DVPGVLRF-NH2, in cells stably expressing the individual re-
ceptor variants. The potency of this agonist was determined
and compared for its ability to mobilize calcium in cells cul-
tured either at 37 or 288C. As can be seen in Figure 3B, signal-
ing through the FLP-18R1b receptor was about 2.6 more efﬁ-
cient at 288C than at 378C (EC50 values and 95% conﬁdence
limits of 17.8 nM/12.8–24.9 nM and 46.0 nM/31.3–67.7 nM,
respectively). Signaling through the shorter receptor isoform,
FLP-18R1a, was even more responsive to the temperature
downshift, which is reﬂected in both about fourfold higher po-
tency (EC50 values and 95% conﬁdence limits: 5.6 nM/3.01–
10.4 nM at 288C and 23.3 nM/7.6–71.9 nM, at 378C) and a 1.7
higher maximal response at 288C (Figure 3A). Since both
receptors were fully functional at 378C, some experiments
were performed solely at this temperature for expedience.
Receptor Binding
Membranes prepared from cells stably expressing the FLP-
18R1a or FLP-18R1b proteins were used in the receptor
binding experiments. The cells were subjected to a 37 to 288C
Table I Calcium Mobilization in Response to C. elegans FLP-18 Peptides and Other FMRF-Amides in CHO Cells Stably
Expressing FLP-18R1a or FLP-18R1b Receptors*
Peptide Species of Origin
FLP-18R1b (Long Form) FLP-18R1a (Short Form)
EC50 (nM) 95% CL (nM) EC50 (nM) 95% CL (nM)
DVPGVLRF-NH2 C. elegans/ﬂp-18 45.9 32.1–65.8 32.3 24.6–43.2
KSVPGVLRF-NH2 C. elegans/ﬂp-18 48.3 35.3–65.9 28.3 29.6–38.8
SEVPGVLRF-NH2 C. elegans/ﬂp-18 58.4 38.6–88.4 25.9 16.0–41.9
SVPGVLRF-NH2 C. elegans/ﬂp-18 43.3 30.4 –61.7 14.1 8.3–24.0
DFDGAMPGVLRF-NH2 C. elegans/ﬂp-18 124.0 81.2 –168.5 117.2 84.3–162.9
EIPGVLRF-NH2 C. elegans/ﬂp-18 44.4 32.8–60.15 13.3 7.6–23.1
AVPGVLRF-NH2 A. suum (AF3) 13.1 10.1–16.9 7.6 5.6–10.4
GDVPGVLRF-NH2 A. suum (AF4) 37.2 21.8–63.3 13.5 8.1–22.4
GMPGVLRF-NH2 A. suum (AF20) 63.1 45.1–88.1 44.6 33.1–60.2
GLGPRPLRF-NH2 A. suum (AF9) or C. elegans/ﬂ-p21 254.1 174.2–370.5 267.0 179.9–396.1
SPLGTMRF-NH2 C. elegans/ﬂp-3 942.6 708.6–1254 886.3 621.6–1264
SAEPFGTMRF-NH2 C. elegans/ﬂp-3 1539 1035–2287 2092 1396–3133
SADDSAPFGTMRF-NH2 C. elegans/ﬂp-3 2880 1794–4623 2398 1659–3466
EDGNAPFGTMRF-NH2 C. elegans/ﬂp-3 1598 993.1–2571 2437 1776–3343
SQPNFLRF-NH2 C. elegans/ﬂp-1 4746 2260–9967 1684 1267–2238
* Cells were cultured at 378C.
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temperature shift and incubation at 288C for 16–24 h before
cell harvesting for membrane preparation.
In a saturation binding experiment, [125I-Y8]-DVP
GVLRF-NH2 was bound with a similar high afﬁnity to both
receptors FLP-18R1a and FLP-18R1b (Kd values of 0.16 and
0.25 nM, respectively). The shorter receptor isoform FLP-
18R1a was expressed in the plasma membrane with a higher
receptor density than the longer variant FLP-18R1b (Bmax
values of 1.12 and 0.67 pmol/mg membrane protein, respec-
tively; Figure 4A).
In competition binding experiments, DVPGVLRF-NH2
potently competed with the radioactive probe at both recep-
tors with Ki values of 3.8 and 2.5 nM for FLP-18R1a and
FLP-18R1b, respectively (Figure 4B).
Signaling Pathways
Strong calcium signaling observed for both receptor isoforms
implied GPCR coupling to Gq protein and signaling via
phospholipase C. However, calcium responses can also result
from a GPCR binding to Gs protein and activating cAMP-
dependent calcium channels as well as from an activated tri-
meric Gi protein(s) yielding a dissociated Gbc subunit,
which can trigger an increase in cellular calcium through a
separate pathway.
To investigate the nature of FLP-18R1a and FLP-18R1b
signaling, clonal cells were grown at 288C, preincubated
with 10 lM phospholipase inhibitor U-73122 or its inactive
analog U-7334319 before a challenge with increasing con-
centrations of DVPGVLRF-NH2. Signaling of both recep-
tors was attenuated, but not completely abolished by U-
73122 but was essentially unaffected by U-73343 (Figures 5A
and 5B). After the U-73122 treatment, the EC50 value for
DVPGVLRF-NH2 changed from 11.3 to 239.2 nM (a 21-fold
increase) at FLP-18R1a and from 8.6 to 426.6 nM (ca. 50-
fold increase) at FLP-18R1b (Figures 5A and 5B).
In a separate experiment to test possible Gi protein
involvement in FLP-18R1a and FLP-18R1b signaling, clonal
cells were grown at 378C and pretreated overnight with PTX
to uncouple the receptors from Gi before measuring calcium
responses to increasing concentrations of DVPGVLRF-NH2.
PTX pretreatment resulted in more active receptors and an
EC50 shift to lower values. The EC50 value for DVPGVLRF-
NH2 decreased from 32.4 to 1.5 nM for FLP-18R1a (Figure
6A) and from 56.1 to 1.0 nM for FLP-18R1b (Figure 6B).
cAMP experiments were carried out with clonal cells
grown at 378C. Exposure to DVPGVLRF-NH2 resulted in
weak (about 15% cAMP increase over the basal) but concen-
tration-dependent cAMP responses (EC50 values of 75.3 and
240 nM for FLP-18R1a and FLP-18R1b, Figures 7A and 7B,
respectively). It is quite possible that if the cAMP assays were
run with cells cultured at 288C, the agonist responses could
have been stronger.
DISCUSSION
Described in this report is the cloning and functional annota-
tion of two alternatively spliced variants of the orphan C. ele-
gans GPCR Y58G8A.4 as receptors activated by peptides
encoded by the ﬂp-18 precursor gene, designated FLP-18R1a
(Y58G8A.4a) and FLP-18R1b (Y58G8A.4b). TheY58G8A.4a
and Y58G8A.4b proteins consist of 397 and 433 amino acids
residues, respectively, and differ both in amino acid sequence
and length in the C-terminal tail. The C-terminal regions
Y58G8A.4a/FLP-18R1a and Y58G8A.4b/FLP-18R1b contain,
respectively, seven and eight possible serine phosphorylation
(only two of them are the same, Ser354 and Ser 357) and
fewer predicted threonine phosphorylation sites. There is
FIGURE 3 Ca2+ mobilization as monitored by FLIPR. Receptor signaling in cells stably trans-
fected with ﬂp-18R1a (panel A) or ﬂp-18R1b DNA (panel B) and cultured either at 37 or 288C in
response to increasing concentrations of DVPGVLRF-NH2.
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FIGURE 5 Effects of a phospholipase inhibitor U-73122 and its inactive analog U-73343 on
DVPGVLRF-NH2-mediated Ca
2+ mobilization in cells stably expressing FLP-18R1a (panel A) or
FLP-18R1b (panel B) as monitored by FLIPR. Cells were incubated overnight at 288C before the
experiment.
FIGURE 4 Receptor binding using membranes expressing the FLP-18R1a or FLP-18R1b recep-
tors prepared from clonal cells cultured at 288C. (A) Direct binding of increasing concentrations of
[125I-Yo]-DVPGVLRF-NH2. (B) Competition binding experiment (see Experimental section for
details).
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only one predicted Tyr phosphorylation site in the C-terminus
of Y58G8A.4b/FLP-18R1b (Tyr404) and none in Y58G8A.4a/
FLP-18R1a (www.cbs.dtu.dk/services/NetPhos/).
Activation of both receptor variants in CHO cells by FLP-
18 peptides resulted in potent, concentration-dependent in-
tracellular Ca2+ mobilization. Three A. suum neuropeptides
AF3, AF4, and AF20 that share the FLP-18 peptides C-termi-
nal motif, -PGVLRF-NH2, were also potent agonists. It is
worth noting that the FLP-18 peptides reported here repre-
sent only putative sequences predicted from the ﬂp-18 pre-
cursor gene at the time of our study.25 Since then, most of
the FLP-18 peptides listed in Table I have been isolated and
sequenced.3,26–28 Recently, SYFDEKKSVPGVLRF-NH2 was
isolated3,27 and EMPGVLRF-NH2 was both predicted and
isolated3,27; neither was included in the current study. When
we tested KSVPGVLRF-NH2 (a predicted sequence
25) and
SVPGVLRF-NH2 (the isolated peptide
26–28), both peptides
were equally potent to activate FLP-18R1b but SVPGVLRF-
NH2 was two fold more potent at the FLP-18R1a receptor
(Table I). It is interesting to note that the shorter peptides
were more potent than longer peptides and that the most
potent was not a C. elegans but an A. suum peptide,
AVPGVLRF-NH2 (EC50 7.6–13.1 nM). The longest C. elegans
FLP-18 peptide DFDGAMPGVLRF-NH2 was the least potent
(EC50 117.2–124 nM). It is also interesting to note that
GLGPRPLRF-NH2 (AF9 or FLP-21 peptide) identiﬁed as a
cognate ligand for the C. elegans NPR-1 receptor11,13 also
activated FLP-181Ra and FLP-18R1b, although with a con-
siderably lower potency (EC50 254–267 nM). It is worth not-
ing that one FLP-1 peptide and also peptides encoded on
ﬂp-3 activated both isoforms of the FLP-18 receptor; how-
ever, with the EC50 in the submicromolar to micromolar
range it is likely that these peptides are not endogenous
ligands for this receptor.
Several FLP-18 peptides were reported to activate NPR-
1/FLP-21-R when this receptor was expressed in oocytes or
C.elegans pharyngeal tissue.13 These ﬁndings suggest a pro-
miscuous nature for the NPR-1 and FLP-18 receptors,
FIGURE 6 Effects of PTX on DVPGVLRF-NH2-mediated Ca
2+ mobilization at 378C in cells sta-
bly expressing FLP-18R1a (panel A) or FLP-18R1b (panel B) as monitored by FLIPR.
FIGURE 7 DVPGVLRF-NH2-mediated cAMP release at 378C in cells stably expressing FLP-
18R1a (panel A) or FLP-18R1b (panel B).
346 Kubiak et al.
Biopolymers (Peptide Science)
which seem to be capable of recognizing multiple FLP
ligands produced by different ﬂp genes or conserved FLPs
from other invertebrates. There are now many examples of
the potentially enormous complexity of peptide actions in
C. elegans, in which a given receptor can bind to multiple
FLPs encoded by distinct genes and a single FLP can bind to
multiple receptors.3,26
Despite different C-termini, the region implicated in dis-
tinct G-protein recognition for many other GPCRs, the same
signaling pathways were observed for both Y58G8A.4 iso-
forms expressed in CHO cells. Gq protein coupling seems to
be the main but not exclusive signaling pathway since cells
pretreated with U-73122, a phospholipase inhibitor, attenu-
ated but did not completely abolish the Ca2+ signal. A much
less pronounced Gs-mediated pathway was also detected by
an agonist-triggered concentration-dependent increase in
cAMP. Somewhat unexpectedly, PTX pretreatment of cells
stably expressing either FLP-18R1a or FLP-18R1b resulted in
more active receptors. Concentration-dependent response
curves for DVPGVLRF-NH2-mediated Ca
2+ mobilization
were left-shifted. This result may not reﬂect a direct contri-
bution of Gi to Ca2+ signaling via the released Gbc subunit
but rather an increased contribution from the receptor-Gs
coupling to open more cAMP-gated Ca2+ channels resulting
from the Gi inactivation by PTX. Possible contributions
from the receptor—Gs couplings were conﬁrmed by cAMP
responses to increased concentrations of an FLP-18 peptide.
However, this effect was rather small and might be due to the
fact that the experiments with Gq signalling were carried out
after the 37 to 288C temperature shift whereas those on Gs
and Gi were carried out at 378C. It is therefore possible that
the higher temperature could have signiﬁcantly diminished
the signaling efﬁciency such that the contribution of Gi/Gs
appears artiﬁcially low.
At present it is not known what the preferred signaling
pathways of the FLP-18R1 receptors are in their native envi-
ronment in C. elegans. As shown by Rogers et al.,13 NPR-1
expressed in Xenopus laevis oocytes coupled to Go/Gi activa-
tion resulting in opening of inwardly rectifying K+ channels.
The NPR-1 coupling to Gi was also demonstrated in CHO
cells.11 However, when the same NPR-1 receptor was ectopi-
cally expressed in the C. elegans pharynx, agonist-mediated
signaling appeared to be mediated through Gq.13 This result
underscores the context-dependent pharmacology of GPCRs,
which must be taken into consideration when interpreting
data from heterologously expressed systems.
In contrast to some earlier deorphanized C. elegans neuro-
peptide GPCRs,11,12 the two FLP-18 receptor variants were
fully functional at 378C when expressed in CHO cells, but
their activity was increased by cell incubation at 288C. The
functional expression of the FLP2 receptor at 378C in CHO
cells was also reported by Mertens et al.14 Therefore, a 37 to
288C temperature shift is absolutely necessary for functional
expression of some, but not all, nematode GPCRs in mam-
malian cells.
As reported previously, we were unable to successfully
generate stable CHO cell lines for the NPR-1/FLP-21-R11 or
FLP-1512 receptors. In contrast, this was not a problem for
both FLP-18R1a and FLP-18R1b. Likewise, Mertens et al.14
obtained stable clonal cell lines for the FLP2 receptor in
CHO cells and for another C. elegans GPCR, C26F1.6, heter-
ologously expressed in HEK293 cells.29 To date, biological
roles for neither the FLP-18 receptors nor the ﬂp-18 precur-
sor have been deﬁned in C. elegans; matching the FLP-18
peptides with their receptors facilitates the experimental
investigation of this system. However, an RNAi approach has
shown that silencing of the ﬂp-18 ortholog in the potato cyst
nematode, Globodera pallida, resulted in a distinctly aberrant
behavioral phenotype, which indicates a key role of the FLP-
18 peptides in motor function.30 Physiological effects of
PGVLRFamides have been observed in other nematodes. For
instance, peptides with this motif were excitatory on A. suum
somatic and ovijector muscle tissue.31–33 Threshold effects
were observed at *1 nM for at least two of these peptides,
though a comprehensive structure–activity relationship has
not been established. They also reduced cAMP levels in so-
matic muscle tissue.33 These data suggest that the FLP-18
receptors are intriguing targets for anthelmintic discovery.
The authors thank Susan Nulf for help with gene cloning, Katherine
Burton for membrane preparations and assistance with FLIPR
experiments and John Davis for assistance with receptor binding
experiments.
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